Latest Breaking News On - European investors - Page 18 : comparemela.com

OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine CoVepiT is a SARS-COV-2 vaccine activating T cell defenses through CD8 T-cell multi-epitope responses. CoVepiT epitopes are selected from 11 viral protein targets and designed to cover all initial and new emerging SARS-CoV-2 variants. CoVepiT, as second-generation vaccine, potentially provides long-term cellular immunity with memory T cells. Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that the Belgian Federal Agency for Medicines and Health Products ( Agence Fédérale des Médicaments et des Produits de Santé AFMPS) and the Belgian Ethics Committee approved the Phase 1 trial evaluating its COVID-19 vaccine, named CoVepiT, on 48 healthy volunteers. First subjects are expected to be enrolled shortly.

Alexis peyrolesChris maggosIsabel leroux roelsFlorence portejoieDarren oplandBelgian federal agency for medicinesBoehringer ingelheimHealth products agenceGhent universityBelgian ethics committeeLifesci communicationsBelgian federal agencyHealth productsDes produits de santChief executive officerNon small cell lung cancer